PHARMACOKINETICS AND METABOLISM OF ANTIEPILEPTIC DRUGS IN ELDERLY PATIENTS

老年患者抗癫痫药物的药代动力学和代谢

• 批准号: 7605957
• 负责人: JAMES C. CLOYD
• 金额: $ 1.83万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605957
• 关键词: Adult; Antiepileptic Agents; Blood specimen; Carbamazepine; Collection; Computer Retrieval of Information on Scientific Projects Database; Dose; Drug Formulations; Drug Kinetics; Elderly; Exhibits; Female; Funding; Goals; Grant; Institution; Intravenous; Kinetics; Label; Metabolism; Oral; Patients; Pharmaceutical Preparations; Phenytoin; Radioactive; Research; Research Personnel; Resources; Source; Time; Treatment Protocols; United States National Institutes of Health; Urine; male; older patient

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our goal is to investigate the effect of advanced age on antiepileptic drug (AED) pharmacokinetics and metabolism. Selected elderly and adult male and female ambulatory patients taking phenytoin (PHT) or carbamazepine (CBZ) for any reason as monotherapy or with other non-interfering medications including other non-interfering AEDs will be evaluated. The patients will receive a portion of their oral dose of CBZ or PHT in a stable-labeled formulation given intravenously as 100 mg over 10 minutes (one time only). Stable-labeled CBZ and PHT are NOT radioactive and exhibit the same kinetics and metabolism as unlabeled CBZ or PHT. Blood samples and urine collections will be analyzed. In the CBZ De-Induction Study, a sub-study of the CBZ Project, subjects receive the intravenous formulation at four time points over three months while being taken off their CBZ regimen and switched to another antiepileptic drug (AED).

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 我们的目标是研究高龄对抗癫痫药物 (AED) 药代动力学和代谢的影响。将评估因任何原因服用苯妥英 (PHT) 或卡马西平 (CBZ) 作为单一疗法或与其他非干扰药物（包括其他非干扰 AED）一起服用的老年和成年男性和女性门诊患者。患者将接受部分口服剂量的 CBZ 或 PHT，采用稳定标记制剂，静脉注射 100 mg，持续 10 分钟（仅一次）。稳定标记的 CBZ 和 PHT 不具有放射性，并且表现出与未标记的 CBZ 或 PHT 相同的动力学和代谢。将分析血液样本和尿液样本。 在 CBZ 去诱导研究（CBZ 项目的子研究）中，受试者在三个月内的四个时间点接受静脉制剂，同时停止 CBZ 治疗方案并改用另一种抗癫痫药物 (AED)。